Exhibit 99.1

 


 

NEOGENOMICS, INC.

PRESS RELEASE

 

 

 

FOR IMMEDIATE RELEASE

 

NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017

 

Gross Margin Improvement to 48.9%

 

Ft. Myers, Florida – February 21, 2018 - NeoGenomics, Inc. (NASDAQ: NEO),

a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2017.

 

Fourth Quarter 2017 Highlights:

 

 

18.7% increase in clinical genetic testing volume(1)

 

12.1% increase in consolidated revenue to $67.8 million

 

10.9% reduction in average cost per clinical genetic test(1)

 

Improvement in Gross Margin to 48.9% from 45.1% in Q4 16

 

GAAP EPS of $0.03 per share and non-GAAP Adj. Diluted EPS(2) of $0.05 per share

 

Full Year 2017 Highlights:

 

 

16.7% increase in clinical genetic testing volume(1)

 

6.0% increase in consolidated revenue to $258.6 million

 

11.3% reduction in average cost per clinical genetic test(1)

 

Improvement in Gross Margin to 46.5% from 45.2% in 2016

 

GAAP EPS of ($0.14) per share and non-GAAP Adj. Diluted EPS(2) of $0.13 per share

 

Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the same period in 2016.  After adjusting 2016 results for the divestiture of PathLogic, revenue growth was 15%.  Clinical genetic test volume(1) increased by almost 19% year over year.  Average revenue per clinical genetic test (“Revenue per Test”) decreased by 8% to $338, primarily due to changes in test mix and reduced reimbursement levels for certain molecular tests.    

 

Consolidated gross profit improved by $5.9 million, or 22%, compared to the fourth quarter of 2016 and consolidated gross margin improved by 380 basis points to 48.9%.  Gross margin improvement was driven by productivity gains and cost efficiencies which resulted in an 11% reduction in average

 


The following information was filed by Neogenomics Inc (NEO) on Wednesday, February 21, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Neogenomics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Neogenomics Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account